Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
BMC Cancer. 2024 Nov 21;24(1):1436.
doi: 10.1186/s12885-024-13210-9.
1 Department of Biomedical Sciences, Humanitas University, Milan, Italy. [email protected].
2 Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy. [email protected].
3 Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
4 Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
5 Department of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain.
6 Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
7 Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy.
8 Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France.
9 Faculté de Médecine, Université Paris Saclay, Kremlin Bicêtre, France.
10 Medical Oncology Department, Gustave Roussy, Villejuif, France.
11 Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
12 Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
13 Department of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
14 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
15 Novartis Pharma AG, Basel, Switzerland.
16 Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA.